HOME >> BIOLOGY >> NEWS
Anti-inflammatory drugs interact with HRT, and more

ndings will need to be addressed in future trials.

Citation: Garcia Rodrıguez LA, Egan K, FitzGerald GA (2007) Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: A drugdrug interaction" PLoS Med 4(5): e157. doi:10.1371/journal.pmed.0040157

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0040157

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-04-05-fitzgerald.pdf

CONTACT:
Dr. Garret A FitzGerald
University of Pennsylvania
Institute for Translational Medicine and Therapeutics
153 Johnson Pavilion
3620 Hamilton Walk
Philadelphia, PA 19104-6084
United States of America
+1 215 898-1185
+1 215 573-9135 (fax)
garret@spirit.gcrc.upenn.edu


Understanding the Slow Depletion of Memory CD4+ T Cells in HIV Infection

Using a simple mathematical model, Andrew Yates and colleagues show that a runaway cycle of T cell activation and infection cannot explain the slow rate of CD4 decline during chronic HIV infection. A related perspective by Rob de Boer discusses the study

Citation: Yates A, Stark J, Klein N, Antia R, Callard R (2007) Understanding the slow depletion of memory CD4 T cells in HIV infection. PLoS Med 4(5): e177. doi:10.1371/journal.pmed.0040177

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pme
'"/>


Contact: Andrew Hyde
press@plos.org
44-122-346-3330
Public Library of Science
21-May-2007


Page: 1 2 3 4 5

Related biology news :

1. Anti-inflammatory effects of omega 3 fatty acid in fish oil linked to lowering of prostaglandin
2. MIT model could predict cells response to drugs
3. New target for HIV/AIDS drugs and vaccine discovered
4. Modified mushrooms may yield human drugs
5. UGR researchers design an alternative to blood test to detect drugs in the body
6. Could fungal collection hold the key to new life-saving drugs?
7. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
8. Scientists develop new drugs to fight colon and breast cancer more effectively
9. Generic biologic drugs unlikely to offer significant savings
10. Stem cells provide new tool for studying disease and identifying ALS drugs
11. Enhancing chemotherapys efficacy: New agent has synergistic effect with standard drugs

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anti inflammatory drugs interact with HRT and more

(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytic ... next step in its expanded strategy to rebuild the ... naming of current Chief Operating Officer, Valerie Palmieri ... Chairman of the Board and CEO James LaFrance ... are effective January 1, 2015. "Jim and ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/17/2014)... LEXINGTON, Mass. , Dec. 17, 2014   ... a biopharmaceutical company developing therapeutic products for rare disorders, ... Healthcare Conference being held in San Francisco, ... , President and Chief Executive Officer, will present on ... p.m. EST).  The presentation will be webcast live and ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
Cached News: